
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
BiotechTV - News
00:00
Monotherapy Responses in Resistant Lung Cancer
Stefanie Fluckiger-Mangual reports durable stable disease, tumor shrinkage, and partial responses with TT125-802 monotherapy in resistant lung cancers.
Play episode from 05:23
Transcript


